We have already also shown a more standard mediation analysis that shows that actually the most explainable factor for the effect on MACE [major adverse cardiovascular events] in the select trial is inflammation
Current formulations of GLP-1 analogs rely primarily on subcutaneous injections, which may pose challenges to patient convenience and long-term adherence
Length of treatment and patient adherence to taking medication are also important
They reduce cravings, particularly for high-fat and high-sugar foods
Think of glucagon as adding a gentle push on your bodys energy expenditure
Abdominal fat loss, as well as sustained reductions of fasting insulin levels and markers of IR, have been also shown to individuals with overweight/obesity, prediabetes, PCOS and OSA during their administration [31, 38, 6770]